Sensei biotherapeutics reports full year 2024 financial results and update on clinical progress

- preliminary efficacy data from phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a pd-(l)1 resistant “hot” tumor patient population -

SNSE Ratings Summary

SNSE Quant Ranking